January 2021 – Ponce Therapeutics

Kevin Slawin In Portfolio, Rapha Capital Management

AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)

Asclepix Therapeutics, Inc. AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME) January 5, 2021

Kevin Slawin In Portfolio, Rapha Capital Management

NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

NexImmune Inc. NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor Zeldis formerly served as Celgene CMO and CEO of Celgene…